Immunoproliferative disorder

Immunoproliferative disorders are a group of diseases characterized by the abnormal proliferation of the primary cells of the immune system, typically B lymphocytes, T lymphocytes, or natural killer cells. These disorders can lead to a variety of clinical manifestations, including lymphadenopathy, hepatosplenomegaly, autoimmune diseases, and increased susceptibility to infections.

Types of Immunoproliferative Disorders[edit | edit source]

Immunoproliferative disorders can be broadly classified into two categories: B cell disorders and T cell disorders.

B Cell Disorders[edit | edit source]

B cell disorders are characterized by the abnormal proliferation of B lymphocytes, leading to an overproduction of antibodies. This can result in a variety of clinical manifestations, including hyperviscosity syndrome, autoimmune hemolytic anemia, and rheumatoid arthritis.

T Cell Disorders[edit | edit source]

T cell disorders are characterized by the abnormal proliferation of T lymphocytes, leading to an overproduction of cytokines. This can result in a variety of clinical manifestations, including hemophagocytic lymphohistiocytosis, lymphoma, and leukemia.

Diagnosis[edit | edit source]

The diagnosis of immunoproliferative disorders typically involves a combination of clinical history, physical examination, and laboratory testing. Laboratory tests may include complete blood count, immunoglobulin levels, and flow cytometry.

Treatment[edit | edit source]

The treatment of immunoproliferative disorders depends on the specific type of disorder and the severity of symptoms. Treatment options may include immunosuppressive therapy, chemotherapy, radiation therapy, and stem cell transplantation.

See Also[edit | edit source]

Immunoproliferative disorder Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.